Vagus nerve stimulation (VNS) is an adjunctive antiepileptic treatment for patients with refractory epilepsy. Limited information on long-term treatment with VNS is available. The purpose of this paper is to present our experience with VNS with a follow-up of up to 4 years.
INTRODUCTION
Approximately 1% of the population suffers from chronic epilepsy. Partial epilepsy is the most common type of epilepsy in adults 1 . According to the literature, about 20% of patients with epilepsy have uncontrolled or poorly controlled seizures despite adequate treatment with antiepileptic drugs (AEDs) 2 . For these patients, epilepsy surgery may represent a therapeutic alternative. This requires a thorough patient selection and only 30-50% of patients can be operated on after extensive pre-surgical evaluation 3 . Implantation with a vagus nerve stimulator is a novel and currently available antiepileptic treatment modality for the remaining patients. Worldwide, more than 3500 patients have been implanted and several mostly short-term studies on efficacy and safety have been published [4] [5] [6] [7] [8] . The current consensus is that a third of patients experience a considerable improvement in seizure control with a reduction in seizure frequency of at least 50%, a third of patients experience a worthwhile reduction of seizure frequency between 30 and 50%. In the remaining third of the patients, there is little or no effect.
Currently limited information is available on patients with refractory partial epilepsy who became seizure-free during vagus nerve stimulation (VNS) 16, 17 . There are no studies that evaluate the clinical, neuroimaging and EEG features of seizure-free patients treated with VNS. The purpose of this paper is to evaluate seizure control in 15 implanted patients with long-term follow-up and to describe in detail the case reports of three out of four patients who experienced long-term (≥12 months) entirely seizure-free intervals.
MATERIALS AND METHODS
At the University Hospital in Gent, 25 patients (12 females and 13 males) have been implanted with a VNS between March 1995 and April 1999. These patients were part of a larger group (n = 150) of patients with medically refractory epilepsy who were included in a pre-surgical evaluation protocol. After video-EEG monitoring, optimum MRI, interictal FDG-PET and neuropsychological assessment, 105/150 patients were found to be unsuitable candidates for resective surgery. In some patients, a confined and resectable epileptic zone could not be identified; in others, resective surgery was contraindicated because of the fear of a possible post-operative cognitive deficit. These patients were offered three alternatives: rematching of standard AEDs, drug-trials with novel AEDs or VNS. Fifty patients continued their medical treatment and had a rematching of standard AEDs, 30 patients were included in phase-3 drug trials with novel AEDs such as topiramate, gabapentin or levetiracetam. Twentyfive patients were offered implantation of a vagus nerve stimulator and gave informed consent. The local ethics committee approved the VNS implantation and study protocol. The first 15 patients (6M, 9F) have sufficient follow-up data for analysis and will be further discussed in this study. Mean follow-up in these 15 patients was 29 months (range 12-48; SD = 11.9). Six out of fifteen patients have a follow-up of 1-2 years; 5/15 have a follow of 2-3 years; 4/15 have a followup of 3-4 years. The mean age of these patients was 30 years (range: 17-44 years; SD = 7.9); the mean duration of epilepsy was 17.5 years (range: 5-35 years; SD = 8.5). All patients but one were on chronic anticonvulsant polytherapy, the mean number of AEDs being 3 (range 1-4; SD = 0.8).
Stimulation of the left vagus nerve was performed using the Neurocybernetic Prosthesis (NCP ) System (Cyberonics Inc., Houston Texas) that comprises two components: the NCP (a generator which is implanted subcutaneously in a subclavicular pouch) and the NCP -lead with two spiral electrodes that are wound around the left vagus nerve in the neck. The surgical procedure, described previously [9] [10] [11] , requires general anaesthesia and takes about 1 hour. Patients were discharged 24 hours after surgery. Stimulation was initiated within 2-4 weeks after surgery. The generator was programmed using a portable computer provided with a programming device and specialized software. The programming device was held upon the patient's chest above the implanted generator to program the various stimulation parameters such as output current, frequency, pulse-width and on/off periods. During follow-up clinic visits, the output current was gradually ramped up with 0.25-0.50 mA per visit until individual patient tolerance or a maximum of 3 mA was reached. The other parameters were programmed according to 'standard stimulation' with a frequency of 30 Hz, pulse width of 500 µs, on/off periods of 30 s/300-600 s. The patients were also provided with a magnet allowing additional stimulation to be commanded by the patient or a bystander in the case of an aura or seizure. The magnet output current was programmed at 0.25 mA higher than the automatically delivered stimulation with a pulse width of 500 µs for a period of 30 s. Standard stimulation was replaced by 'rapid cycle stimulation' (on/off periods = 7 s/14 s) in patients who did not respond to standard stimulation parameters. This has been shown to be effective in some patients 12 . Patients were followed on an outpatient basis at regular intervals, usually every 2-4 weeks during ramping up. Afterwards patients were seen every 1-3 months for further follow-up. At every clinic visit, seizure frequency, seizure type, prescribed AEDs and dosage as well as any side effects of VNS were assessed. In every patient, we prospectively assessed the decrease of seizure frequency in relation to stimulation output current and type (standard vs. rapid cycle), seizure type(s) suppressed by VNS, change in duration of seizures, and duration of seizurefree intervals. Seizure frequency during the year before and the full follow-up period after the day of implantation was compared using the Wilcoxon signedrank test (WSRT). Using the same statistical test, we also compared the maximum complex partial seizures (CPS)-free days in the year before VNS and follow-up time after VNS. Because of difficulties in accountability, simple partial seziures (SPS) were not included in this analysis.
RESULTS
In all 15 patients the surgical procedure was uncomplicated and the post-operative period was uneventful. The patients were discharged from the hospital 24 hours after surgery. After ramping up during 2-4 months, mean stimulation output was 2.25 mA (range 1.5-3 mA; SD = 0.6). Usually, the occurrence of coughing and/or an unpleasant sensation in the throat was the limiting factor for further increasing the output current.
During follow-up, the patients showed a mean reduction in CPS frequency from 14 seizures per month (range: 2-40 per month; SD = 13.8) to 8 seizures per month (range: 0-30 per month; SD = 12.1). This reduction is statistically significant (P = 0.0016; WSRT). One patient showed clusters of up to 10 CPS a day (200 seizures per month) and had a clear-cut reduction of this seizure frequency. This patient was not included in the analysis for statistical reasons. Six patients were free from CPS during a ≥12-month interval. Four our of six patients experienced an entirely seizure-free interval of 12 months or more. Two out of six patients still have SPS but stopped having CPS within 3 months after stimulation initiation. Four other patients had a seizure reduction of more than 50%; two patients had a worthwhile reduction of seizure frequency between 30-50%; in three patients, seizure reduction was less than 30% or seizure frequency remained unchanged.
A reduction in seizure frequency of ≥50% was achieved within the first 4 months after initiation of stimulation in 8/10 patients, amongst whom were all six patients with seizure-free intervals of ≥12 months. At the time of evaluation, 6/13, who frequently had secondary generalized tonic-clonic seizures before implantation, were free of convulsions. Five out of seven patients who still experience secondary generalization have had a ≥50% reduction in frequency and/or duration of convulsions.
The mean maximum complex partial seizurefree interval changed from 9 days (range: 1-30 days; SD = 8.1) to 312 days (range: 3-1430 days; SD = 469.1). This change in seizure-free interval is statistically significant (P = 0.0007; WSRT). Patients with a ≥50% reduction of seizure frequency had a mean pre-implantation seizure frequency of 5.9 vs. 13, 7 (n.s.; P = 0.0646) in the total population. The number and average dosage of AEDs remained unchanged in 10 patients. In one patient, tapering of two AEDs reduced polytherapy but in four patients one adjunctive AED had to be administered. Three out of four patients that are currently free from all types of seizures never had any change of AED treatment. One out of four had a trial with vigabatrin and later on with lamotrigine. Two patients who are free from CPS but still experience SPS had trials with novel AEDs without additional benefit regarding the occurrence of SPS.
At the first stimulation with 0.25 mA output current, almost all patients reported a funny and indescribable sensation in the throat, as if they were to swallow. Each time the output was gradually increased, this sensation reoccurred and subsided spontaneously within 48 hours. This throat sensation was considered a minor and intrinsic side effect causing no pain or real discomfort.
Six patients reported true side effects. Two of these patients complained of mild intermittent hoarseness or voice alteration during stimulation and one patient experienced dysphagia at the time of stimulation. These side effects did not require any change of stimulation output and subsided over a time period of several weeks. However, three patients reported persistent coughing and additional unpleasant chest, throat or neck sensations during the ramping-up period. This required a temporary reduction of the output current but none of the patients requested that the stimulation be turned off. Nine patients did not report any side effects at all.
CASE-REPORT # 1
UP is a 36-year-old right-handed male who suffered from epilepsy since age 11. He had complicated febrile seizures as a toddler. At age eight, he experienced a severe head trauma with subsequent coma lasting 4 months. At age 11, he started having CPS consisting of a rising epigastric sensation followed by impairment of consciousness and semipurposeful behaviour. From adolescence on, these seizures frequently evolved into secondary generalization. At the time of evaluation he had at least two secondary generalized seizures per week. After extensive trials with all available AEDs in various combinations including vigabatrin and lamotrigine, the patient was evaluated for epilepsy surgery. Video-EEG monitoring confirmed the existence of partial seizures with strikingly fast secondary generalization. Neither were there clinically lateralizing features, nor could the ictal EEG be lateralized. Interictal EEG showed bilateral independent epileptic discharges and no consistent focus. Optimum MRI showed bilateral hippocampal atrophy, more obvious on the right side. FDG-PET revealed widespread right temporal hypometabolism. Neuropsychological testing showed a mild mental retardation and severe psychological instability. The patient was considered unable to cope with the necessary invasive evaluations such as intracranial video-EEG monitoring and therefore unsuitable for further pre-surgical assessment. In March 1995, he was implanted with a vagus nerve stimulator. At that time he was treated with carbamazepine and sodium valproate. In the first weeks during ramping up, he complained of hoarseness at the time of stimulation. Within 3 months, there was a reduction of seizure frequency of 50%. Side effects due to stimulation subsided during further ramping up. Since September 1996, the output current of the stimulator has been 2.25 mA. Apart from a temporary decrease of convulsions, there was no further improvement of seizure control despite the initiation of rapid cycle stimulation. Lamotrigine was added to the antiepileptic therapy of the patient in February 1997 at an initial dosage of 25 mg a day and was increased by the same amount every week until reaching a total dosage of 300 mg bid. Shortly after the administration of lamotrigine, when he was on 100 mg bid, the patient became entirely seizure-free. After 12 months of complete seizure-freedom the patient insisted on reducing lamotrigine. During tapering he had two tonic-clonic seizures. Therapy was reinstalled and the patient has remained completely seizure-free since. 
CASE-REPORT # 2
BI is a 39-year-old right-handed man who developed epilepsy at age 23. He had a severe head trauma due to a car accident at age 10. Habitual seizures occurred weekly and began with a strange and indescribable feeling with occasional automatisms followed by deviation of the patient's head to the left and elevation of his left arm. There was loss of consciousness and subsequent secondary generalization. Despite adequate trials with all available AEDs, there was no reduction of seizure frequency. At least once a month, the patient was brought into the emergency room with severe head trauma due to seizures. While being treated with three different AEDs, his maximum seizure-free period was 1 week. At the time of evaluation on the monitoring unit he had four habitual seizures with clinical characteristics suggestive of supplementary motor area onset. The ictal EEG showed a right hemispheric epileptic recruitment; interictally there was diffuse slowing. Optimum MRI revealed bilateral hippocampal signal abnormalities and a left temporal arachnoidal cyst. PET turned out normal. On neuropsychological assessment, the patient presented a disharmonic profile with a frontal dysfunction but no lateralizing signs. Because of the discrepancies between the results of the different pre-surgical tests, the patient was no longer considered a suitable candidate for resective surgery. In September 1995, he was implanted with a vagus nerve stimulator. At the time of implantation he was treated with carbamazepine, sodium valproate and vigabatrin. After the operation he became entirely seizure-free. In June 1996, he experienced a shortlasting CPS after a quarrel with colleagues at work but has remained free of seizures since. Stimulation output current is 1.5 mA. Apart from mild transient hoarseness, the patient did not report any side effects. AED treatment has been unchanged since the implantation.
CASE-REPORT # 3
VJC is a 44-year-old right-handed woman who was diagnosed with meningitis complicated by a brain abscess in her right hemisphere at age 8. As a result she developed a partial hemiparesis of the left side of her body and recurrent epileptic seizures. Habitual seizures began with an uncomfortable feeling in her stomach followed by staring and loss of contact for about two minutes. There was a prolonged postictal period of confusion. Despite treatment with several AEDs, she had monthly seizures. Occasionally the patient experienced secondary generalization during night time. Video-EEG monitoring documented CPS with secondary generalization. Ictal onset was located in the right hemisphere but differentiation between temporal or frontal onset could not be made. Interictally, there was irregular slow activity on right-sided frontocentro-temporal electrodes, but there were no focal epileptic discharges. MRI showed right hemispheric porencephaly and gliosis in a large area of the parietal, frontal and temporal lobes on the right side. This was consistent with FDG-PET findings that revealed an ametabolic area in the same region surrounded by a larger hypometabolic area. Because of the extent of the lesion and difficulty in defining the area of ictal onset, the patient was no longer considered a suitable candidate for resective surgery.
She was ultimately implanted with a vagus nerve stimulator in October 1997. At that time she was treated with lamotrigine. Stimulation was initiated and ramped up to an output current of 1.25 mA. Since the implantation, the patient has been completely seizurefree and has experienced no side effects.
DISCUSSION
VNS is presently used in patients with severe medically refractory epilepsy who are not surgical candidates or who failed resective epilepsy surgery 13, 14 . Most implanted patients are adults but a small series of children have been implanted in the context of clinical trials with results comparable to those obtained in adults 12, 15 . In the course of an ongoing antiepileptic treatment, it is not always clear which treatment changes are responsible for improvement of seizure control. In our center, none of the patients treated with VNS were included in controlled clinical trials. Hence, adjustment of stimulation parameters and AEDs were at the discretion of the treating physician. Due to the open and descriptive design of this study, the reduction in seizure frequency that was observed in some patients may represent: (a) a true effect of chronic VNS with standard stimulation parameters, (b) an effect of VNS with acute or chronic rapid cycle stimulation, (c) a synergistic effect between VNS and AEDs, (d) a reflection of the natural history of the epilepsy or, (e) more unlikely, a placebo effect.
There are very few reports in the literature on the long-term (>2 years) efficacy of chronic VNS 16, 17 .
Results from these studies indicate that VNS remained an effective adjunctive therapy for medically refractory partial seizures during a follow-up period of 18 months. A trend towards improved seizure control with longer use of VNS was observed. Response during the first 3 months of treatment seemed predictive of long-term response. Our results are generally in agreement with these findings. All our patients with seizure-free intervals of 12 months or more had an initial reduction of seizure frequency of ≥50% within 4 months after a vagus nerve stimulator was implanted. Deterioration of seizure frequency after initial improvement was not observed. In the previously published studies, there is no information available on seizure-free patients. More specifically, it is unknown whether reduction of seizure frequency in the first 3 months of treatment heralds seizure freedom in the following months. In this study, the high number of completely seizure-free patients (4/15) does not match with the results of previous large multicentered trials [4] [5] [6] [7] [8] . While selection bias in our small series is likely, our findings further confirm the previously reported lasting and incremental efficacy of VNS. In our population, patients who gradually improved seemed to have had a gradual effect not only on seizure frequency but on seizure severity as well. In all but two patients, the number and duration of secondary convulsions was decreased when therapeutic output current was reached; half of the patients became completely free of this type of seizures. A subgroup of patients became free of CPS immediately after implantation. The effect the first stimulation trains exert on the vagus nerve and on the underlying epilepsy is presently unclear. Possibly this is the result of an overlap between the effect of anaesthesia or a placebo effect immediately post-operatively and the initiation of stimulation.
There are some reports in animal, as well as in human, research on incremental improvement of seizure control when different stimulation parameters are used 12, 18 . In our study, alteration to rapid cycle parameters did not result in immediate seizure reduction. However, some of our patients remained on rapid cycle stimulation for several months at which time they did experience improved seizure control. Only prospective randomized trials with cross-over design comparing standard with other stimulation parameters will allow for clinically relevant conclusions about the additional benefit and timing of a particular stimulation mode.
Some previous research has suggested that VNS acts through a release of inhibitory neurotransmitters such as GABA and glycine in widespread brain structures 19, 20 . Since several AEDs have a similar mode of action, a synergistic effect between VNS and AEDs is not unlikely. In one of our patients, the administration of lamotrigine clearly made the difference. Whether this is due to a synergistic effect with VNS remains to be proven. Further research on the mechanism of action as well as the analysis of a larger patient population will be necessary to identify potentially useful combinations of VNS and specific AEDs.
Because of the long history of refractory seizures in our series, long-term seizure freedom in 4/15 patients is unlikely to be due to the natural course of the epilepsy or to a placebo effect that is generally short lasting.
The presently available literature and our experience provide little information on how and when to taper medication in responders after implantation of VNS. We tried tapering a single AED in a patient who had been seizure-free for 1 year. This resulted in an immediate recurrence of seizures. Higher baseline seizure rate and later age of epilepsy onset have been reported to be positive predictive factors for outcome 21 . In our population we observed quite an opposite trend for baseline seizure frequency. Age of onset was not a predictive factor. Analysis of the clinical characteristics, seizure type(s), results of EEG and imaging studies in the responders and in particular, the seizure-free patients did not reveal consistent findings. Analysis of these characteristics in a larger population of responders versus non-responders is necessary to identify the best candidates for VNS. Only results of large multicentered studies will allow for a more precise patient selection and better estimation of outcome.
